top of page
tokers-guide-find-the-best-weed-in-dc-lo
NEW 1 to 1 photo editing 122024 (17).png
Former U.S. House Speaker Newt Gingrich is advocating for the therapeutic use of ibogaine for serious mental and physical health conditions, despite its Schedule I classification in the U.S. He highlights its potential for treating addiction and references a Stanford University study on its effectiveness for PTSD, anxiety, and depression in veterans. Texas has also passed legislation to research ibogaine for substance use disorders. Other figures like a Navy SEAL veteran, HHS Secretary Kennedy, and VA Secretary Doug Collins are also promoting psychedelic therapy research and access for veterans.

Former GOP Speaker Promotes Ibogaine as Cutting-Edge Treatment

Sep 26, 2025

Source:

Kyle Jaeger

Marijuana Moment

Former House Speaker Newt Gingrich is becoming a vocal advocate for the therapeutic power of ibogaine, a potent psychedelic. On his podcast, Gingrich explored how this "cutting-edge" science could revolutionize treatment for severe addiction and mental health struggles, particularly for veterans facing PTSD. He highlighted the irony that while common drugs like aspirin are grandfathered into our system, ibogaine remains a restricted Schedule I substance despite showing significant promise in studies from places like Stanford.

This shift isn't just talk; Texas has already greenlit a state-backed research consortium for ibogaine trials. Within the Trump administration, figures like HHS Secretary Kennedy are also signaling a commitment to expanding psychedelic access for veterans within the next year.

For the cannabis community, this mainstreaming of psychedelic research is a massive win. It challenges the "war on drugs" narrative and pushes for a more scientific, health-focused approach to plant medicine. As these high-profile figures advocate for better accessibility and reduced regulatory hurdles, it paves the way for a future where natural therapies are respected and available to those who need them most.

Recent Reviews

bottom of page